Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Axovant Sciences (AXON) Job Posting Could Suggest NDA Filing - Chardan Capital Markets
-
Axovant Sciences (AXON): Reiterating Sell - Chardan
-
Chardan Closes Biotie/Axovant (AXON) Preference Following Acorda Deal; Reaffirms at 'Sell'
-
Axovant Sciences (AXON) Defended at RBC Capital
-
Chardan Capital Affirms Axovant Sciences (AXON) at 'Sell'; Sees as Mispriced Following vTv Therapeutics (VTVT) IPO
-
Chardan Capital Sees Axovant's (AXON) RVT-101 Only Costing $5M Upfront; 'Sell' Rating Affirmed
-
Chardan Capital Trims PT on Axovant (AXON) to $9.50; News is Good, but 24+ Late-Stage Alzheimer's Drugs in Development
-
Pre-Open Stock Movers 06/18: (LMNS) (DGLY) (BMRN) Higher; (HERO) (RATE) (ORCL) Lower (more...)
-
Chardan Capital Markets Starts Axovant Sciences (AXON) at Sell; RVT-101 Remains Overrated
